Literature DB >> 16906583

Clinical utility of assessing ZAP-70 and CD38 in chronic lymphocytic leukemia.

Laura Z Rassenti1, Thomas J Kipps.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16906583     DOI: 10.1002/cyto.b.20129

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


× No keyword cloud information.
  6 in total

1.  Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.

Authors:  Rainer Claus; David M Lucas; Amy S Ruppert; Katie E Williams; Daniel Weng; Kara Patterson; Manuela Zucknick; Christopher C Oakes; Laura Z Rassenti; Andrew W Greaves; Susan Geyer; William G Wierda; Jennifer R Brown; John G Gribben; Jacqueline C Barrientos; Kanti R Rai; Neil E Kay; Thomas J Kipps; Peter Shields; Weiqiang Zhao; Michael R Grever; Christoph Plass; John C Byrd
Journal:  Blood       Date:  2014-05-27       Impact factor: 22.113

2.  Combined normal donor and CLL: Single tube ZAP-70 analysis.

Authors:  Heba A Degheidy; David J Venzon; Mohammed Z H Farooqui; Fatima Abbasi; Diane C Arthur; Wyndham H Wilson; Adrian Wiestner; M A Stetler-Stevenson; Gerald E Marti
Journal:  Cytometry B Clin Cytom       Date:  2011-10-26       Impact factor: 3.058

3.  Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy.

Authors:  Neil E Kay; Jeanette E Eckel-Passow; Esteban Braggio; Scott Vanwier; Tait D Shanafelt; Daniel L Van Dyke; Diane F Jelinek; Renee C Tschumper; Thomas Kipps; John C Byrd; Rafael Fonseca
Journal:  Cancer Genet Cytogenet       Date:  2010-12

4.  Methodological comparison of two anti-ZAP-70 antibodies.

Authors:  Heba A Degheidy; David J Venzon; Mohammed Z H Farooqui; Fatima Abbasi; Diane C Arthur; Wyndham H Wilson; Adrian Wiestner; M A Stetler-Stevenson; Gerald E Marti
Journal:  Cytometry B Clin Cytom       Date:  2011-04-06       Impact factor: 3.058

5.  Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia.

Authors:  C Steininger; L Z Rassenti; K Vanura; K Eigenberger; U Jäger; T J Kipps; C Mannhalter; S Stilgenbauer; T Popow-Kraupp
Journal:  Eur J Clin Invest       Date:  2009-06       Impact factor: 4.686

6.  FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia.

Authors:  Fu Jun Li; Shouluan Ding; Jicun Pan; Mikhail A Shakhmatov; Elena Kashentseva; Jiongru Wu; Yufeng Li; Seng-jaw Soong; Nicholas Chiorazzi; Randall S Davis
Journal:  Blood       Date:  2008-02-26       Impact factor: 22.113

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.